ClearBridge Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $182M | Buy |
557,099
+549,322
| +7,063% | +$179M | 0.15% | 142 |
|
|
2025
Q1 | $2.1M | Buy |
+7,777
| New | +$2.1M | ﹤0.01% | 604 |
|
|
2023
Q3 | – | Sell |
-83,185
| Closed | -$15.8M | – | 689 |
|
|
2023
Q2 | $15.8M | Buy |
83,185
+6,911
| +9% | +$1.31M | 0.01% | 468 |
|
|
2023
Q1 | $15.3M | Buy |
76,274
+19,614
| +35% | +$3.93M | 0.01% | 469 |
|
|
2022
Q4 | $13.5M | Buy |
+56,660
| New | +$13.5M | 0.01% | 484 |
|
|
2020
Q3 | – | Sell |
-365
| Closed | -$54K | – | 788 |
|
|
2020
Q2 | $54K | Hold |
365
| – | – | ﹤0.01% | 784 |
|
|
2020
Q1 | $40K | Sell |
365
-12
| -3% | -$1.32K | ﹤0.01% | 791 |
|
|
2019
Q4 | $44K | Hold |
377
| – | – | ﹤0.01% | 841 |
|
|
2019
Q3 | $30K | Hold |
377
| – | – | ﹤0.01% | 888 |
|
|
2019
Q2 | $27K | Hold |
377
| – | – | ﹤0.01% | 911 |
|
|
2019
Q1 | $35K | Hold |
377
| – | – | ﹤0.01% | 875 |
|
|
2018
Q4 | $27K | Hold |
377
| – | – | ﹤0.01% | 933 |
|
|
2018
Q3 | $33K | Hold |
377
| – | – | ﹤0.01% | 953 |
|
|
2018
Q2 | $37K | Sell |
377
-1,745
| -82% | -$171K | ﹤0.01% | 895 |
|
|
2018
Q1 | $253K | Sell |
2,122
-394
| -16% | -$47K | ﹤0.01% | 731 |
|
|
2017
Q4 | $320K | Sell |
2,516
-1,502
| -37% | -$191K | ﹤0.01% | 719 |
|
|
2017
Q3 | $472K | Sell |
4,018
-219
| -5% | -$25.7K | ﹤0.01% | 689 |
|
|
2017
Q2 | $338K | Buy |
4,237
+3,134
| +284% | +$250K | ﹤0.01% | 712 |
|
|
2017
Q1 | $57K | Hold |
1,103
| – | – | ﹤0.01% | 862 |
|
|
2016
Q4 | $41K | Buy |
1,103
+18
| +2% | +$669 | ﹤0.01% | 895 |
|
|
2016
Q3 | $74K | Buy |
1,085
+491
| +83% | +$33.5K | ﹤0.01% | 834 |
|
|
2016
Q2 | $33K | Buy |
+594
| New | +$33K | ﹤0.01% | 893 |
|